Radient Pharmaceuticals Participates in American Association of Clinical Chemists Annual Meeting and Clinical Lab Expo
TUSTIN, CA, Jul 21, 2011 (MARKETWIRE via COMTEX) -- Radient Pharmaceuticals Corporation "the Company" or "Radient" (otcqx:RXPC) (pinksheets:RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it will participate in the American Association of Clinical Chemists (AACC) Annual Meeting and Clinical Lab Expo in Atlanta, Georgia from July 24 through 28. The company's sales and marketing executives will be representing Radient and its FDA-cleared Onko-Sure(R) cancer test at booth #3719. AACC's annual meeting, the world's largest lab conference, attracts about 17,000-19,000 registrants from more than 100 countries.
"We look forward to AACC next week where, not only will Onko-Sure(R) be displayed, our sales and marketing executives will engage in meaningful dialog with medical device and diagnostics distributors and labs from around world as well as the US," stated Radient's CEO and Chairman, Mr. Douglas MacLellan. "There are several international territories in which we are looking to make deeper inroads. In the US we are looking to have our test offered by a growing number of labs. We have already opened a dialog with several companies attending the conference and we expect further progress towards solidifying those relationships."
